

Breadcrumb

Entity Print



Olaf Penack
TCWP Chair (ELECTED APRIL 2025, PREVIOUS CHAIR: Zinaida Perić)
Germany

Major achievements

Despite all our efforts and progress in our field, significant clinical challenges remain, which TCWP addresses by optimising current management and improving the evidence base for developing new treatment strategies.

In 2025, we:

- improved scientific and educational output and quality by expanding collaboration with other EBMT Working Parties.
- strengthened our partnerships with the EBMT Nurses Group. We integrated nursing-specific content into our scientific and educational activities.
- intensified collaboration with patient representatives to ensure patient-centred scientific action.
- planned, conducted, analysed, and published studies on complications following stem cell transplantation and cellular therapies.
- published evidence-based recommendations for the clinical management of patients with complications following CAR-T cell therapy.
- organised two educational Meetings:
    - Complications post CAR-T Cell Therapy in Paediatric and Adult Patients, 16-18 January 2025, Malaga, Spain
    - Transplant Complications Working Party Educational Meeting, 1-3 October 2025, Dubrovnik, Croatia

Continued to build up and consolidate the TCWP team, which will further improve effectiveness and scientific output in the future.



TCWP team, Dubrovnik, Croatia

Principal research studies

Severity and response criteria in transplant-associated thrombotic microangiopathy
Study type
Retrospective Studies
Diseases
All diseases
Group
Complications Working Party (CWP)
Type of treatment

Allogeneic
Principal investigator
Ivan Moiseev
Treatment and outcome of sHLH after allogeneic hematopoetic stem cell transplantation
Study type
Retrospective Studies
Diseases
All diseases
Group
Complications Working Party (CWP)
Type of treatment
Allogeneic
Principal investigator
Polona Novak
CAR-T cell outcomes in patients with comorbidities
Study type
Retrospective Studies
Diseases
All diseases
Group
Complications Working Party (CWP)
Type of treatment
CAR T
Principal investigator
Fabio Andreozzi; Silvia Escribano Serrat
Long-term outcomes of PTCy vs. ATG in MRD, MUD, MMUD
Study type
Retrospective Studies
Diseases
All diseases
Group
Complications Working Party (CWP)
Type of treatment
Allogeneic
Principal investigator
Hélène Schoemans

Multicentric evaluation of CAR-T cell induced pseudoprogression prevalence (PrevCARTiPP)
Study type
Retrospective Studies
Diseases
All diseases
Group
Complications Working Party (CWP)
Type of treatment
CAR T
Principal investigator
Friedrich Stoelzel

Key publications

2025
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Group
Complications Working Party (CWP)
Paediatric Diseases Working Party (PDWP)
1st listed author
Guillermo Ortí
Journal
Leukemia.
2025
Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Group
Complications Working Party (CWP)
Practice Harmonisation and Guidelines Committee
1st listed author
Charlotte E Graham
Journal
Lancet Oncol.
2025

Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee

Group

Complications Working Party (CWP)

Practice Harmonisation and Guidelines Committee

1st listed author

Guillermo Ortí

Journal

Bone Marrow Transplant.

2025

GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party

Group

Complications Working Party (CWP)

1st listed author

Olaf Penack

Journal

Leukemia.

2025

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

Group

Complications Working Party (CWP)

1st listed author

Nico Gagelmann

Journal

Blood Cancer J.

See the full list of the TCWP 2025 publications



Indicators


	2023	2024	2025
Impact factor	44.70	99.90	**105.50**
Oral presentations	1	4	**2**
Poster presentations	9	4	**1**
Educational events	1	2	**2**

Major educational events




Event

51st Annual Meeting of the EBMT



Event

Transplant Complications Working Party Educational Meeting



ia

Event

RESCHEDULED Complications post CAR-T Cell Therapy in Paediatric and Adult Patients

Jan 16, 2025 - Jan 18, 2025 / Málaga, Spain
Discover more
VISIT THE TCWP WEBPAGE